Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Geratherm Medical AG (GME.DE)
Geschwenda, DE
Geratherm Medical AG, a German-based medical technology enterprise, organizes its operations across four primary divisions: Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems. The Healthcare Diagnostic unit offers a range of items including clinical thermometers, blood pressure monitors, and various self-test diagnostic products designed for women, such as pregnancy tests, chlamydia screens, urinary tract infection indicators, diverse ovulation solutions, and pH tests. Its Respiratory segment is dedicated to the development and production of equipment primarily for diagnosing pulmonary and cardiopulmonary function. Under the LMT brand, the Medical Warming Systems division manufactures MRI-compatible incubators for premature and newborn infants. The Cardio/Stroke segment provides analytical products aimed at assessing stroke risk by detecting atrial fibrillation. The company markets its healthcare solutions via pharmacies, hospitals, and clinics, and successfully exports its merchandise to approximately 60 nations worldwide. Established in 1990, Geratherm Medical AG's headquarters are situated in Geschwenda, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +1.85% | -1.79% | -1.08% | -22.75% | -4.51% | -13.79% | -63.33% | -75.56% | -78.33% | -71.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-27.2% Q4'25: +17.7% (vs Q4'24)
-
EPS growth Medical - Devices: +28.5%-215.4% Q4'25: -132.2% (vs Q4'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%+7.9% Q4'25: +5.2% (vs Q4'24)
-
EBIT margin Medical - Devices: +6.2%-8.8% Q4'25: -7.0% (vs Q4'24)
-
ROIC Medical - Devices: +3.3%-10.4% Q4'25: -7.9% (vs Q4'24)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: +0.8% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-16.01× Q4'25: 12.43× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
21.59M
est: 21.36M (+1.1%)
|
22.06M
est: 21.36M (+3.3%)
|
21.03M
est: 22.01M (-4.5%)
|
21.52M
est: 24.31M (-11.5%)
|
19.85M
est: 26.00M (-23.6%)
|
27.47M
est: 28.37M (-3.2%)
|
25.85M
est: 24.20M (+6.8%)
|
20.96M
est: 25.30M (-17.2%)
|
20.43M
est: 17.80M (+14.7%)
|
14.86M
est: 15.60M (-4.7%)
|
15.00M
15.00M – 15.00M
-3.8% YoY
|
15.90M
15.90M – 15.90M
+6.0% YoY
|
16.90M
16.90M – 16.90M
+6.3% YoY
|
| EBITDA |
4.52M
est: 3.08M (+46.6%)
|
4.58M
est: 3.08M (+48.4%)
|
2.05M
est: 3.18M (-35.5%)
|
2.66M
est: 3.51M (-24.2%)
|
2.57M
est: 3.75M (-31.4%)
|
4.35M
est: 4.10M (+6.1%)
|
3.37M
est: 3.49M (-3.6%)
|
4.18M
est: 3.65M (+14.6%)
|
2.95M
est: 1.97M (+49.7%)
|
-154.6K
est: 1.73M (-109.0%)
|
1.66M
1.66M – 1.66M
-3.8% YoY
|
1.76M
1.76M – 1.76M
+6.0% YoY
|
1.87M
1.87M – 1.87M
+6.3% YoY
|
| EBIT |
3.63M
est: 1.60M (+127.1%)
|
3.40M
est: 1.60M (+112.8%)
|
908.4K
est: 1.65M (-44.9%)
|
1.85M
est: 1.82M (+1.5%)
|
1.27M
est: 1.95M (-34.8%)
|
3.04M
est: 2.12M (+43.1%)
|
1.89M
est: 1.81M (+4.5%)
|
2.48M
est: 1.89M (+30.7%)
|
1.09M
est: 624.7K (+74.6%)
|
-1.31M
est: 547.4K (-339.9%)
|
526.4K
526.4K – 526.4K
-3.8% YoY
|
558.0K
558.0K – 558.0K
+6.0% YoY
|
593.1K
593.1K – 593.1K
+6.3% YoY
|
| Net Income |
2.70M
est: 2.27M (+18.8%)
|
2.24M
est: 2.27M (-1.6%)
|
679.8K
est: 2.33M (-70.8%)
|
1.15M
est: 2.60M (-55.6%)
|
289.9K
est: 2.65M (-89.1%)
|
2.05M
est: 3.63M (-43.6%)
|
1.02M
est: 865.9K (+18.2%)
|
1.11M
est: 1.41M (-21.0%)
|
705.2K
est: 270.6K (+160.6%)
|
-819.0K
est: 54.1K (-1,613.3%)
|
108.2K
108.2K – 108.2K
+100.0% YoY
|
378.8K
378.8K – 378.8K
+250.0% YoY
|
541.2K
541.2K – 541.2K
+42.9% YoY
|
| SGA |
4.47M
est: 3.81M (+17.3%)
|
4.55M
est: 3.81M (+19.5%)
|
4.37M
est: 3.92M (+11.5%)
|
4.63M
est: 4.33M (+6.8%)
|
4.21M
est: 4.63M (-9.2%)
|
4.57M
est: 5.05M (-9.6%)
|
3.80M
est: 4.31M (-11.8%)
|
4.58M
est: 4.51M (+1.6%)
|
3.30M
est: 3.14M (+5.0%)
|
2.35M
est: 2.75M (-14.7%)
|
2.65M
2.65M – 2.65M
-3.8% YoY
|
2.81M
2.81M – 2.81M
+6.0% YoY
|
2.98M
2.98M – 2.98M
+6.3% YoY
|
| EPS |
0.55
est: 0.42 (+31.0%)
|
0.45
est: 0.42 (+7.1%)
|
0.14
est: 0.43 (-67.4%)
|
0.23
est: 0.48 (-52.1%)
|
0.06
est: 0.49 (-88.0%)
|
0.41
est: 0.67 (-38.8%)
|
0.19
est: 0.16 (+18.8%)
|
0.21
est: 0.26 (-19.2%)
|
0.13
est: 0.05 (+160.0%)
|
-0.15
est: 0.01 (-1,600.0%)
|
0.02
0.02 – 0.02
+100.0% YoY
|
0.07
0.07 – 0.07
+250.0% YoY
|
0.10
0.10 – 0.10
+42.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christian Frick | Chief Executive Officer & Member of Management Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GME.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
